Fatty acids in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 6, 2000, Pages 530-532

  Freedman, Steven D ^a,b   Shea, Julie C ^a   Blanco, Paola G ^a   Alvarez, Juan G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL MODEL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; ESSENTIAL FATTY ACID DEFICIENCY; HUMAN; KNOCKOUT MOUSE; LUNG DISEASE; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 0033779274     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200011000-00012     Document Type: Review

References (16)

1. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas
2. Essential fatty acid deficiency in well nourished young cystic fibrosis patients
3. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of the cystic fibrosis patients
4. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis
5. A respiratory disease syndrome in chickens fed essential fatty acid deficient diets
6. The essential fatty acid deficient chicken as a model for cystic fibrosis
7. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis
8. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa
9. Fatty acids inhibit apical membrane chloride channels in airway epithelia
10. A comparison of the effects of linolenic acid (18:3Ω3) and docosahexaneoic acid (22:6(gW)3) acids on phospholipid bilayers
11. Docosahexaneoic acid increases permeability of lipid vesicles and tumor cells
12. Effect of docosahexaneoic acid on mouse mitochondrial membrane properties
13. Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis
14. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis
15. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis
16. A membrane lipid imbalance plays a role in the phenotype expression of cystic fibrosis in cftr -/- mice